Breaks Categories: News

MondayJun 16, 2025 9:20 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique firm specializing in life sciences. The collaboration comes as NRx advances toward two NDA filings, an ANDA submission, and expands its interventional psychiatry clinic acquisitions. Led by veterans of The Trout Group, astr will support NRx and HOPE with investor targeting, message development, earnings prep, and institutional outreach to enhance visibility and engagement. To view the full press release, visit https://nnw.fm/hL3y3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on…

Continue Reading

MondayJun 16, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG

HeartBeam’s credit card-sized device demonstrated 93.4% diagnostic agreement with standard ECGs VALID-ECG study results presented at Heart Rhythm Society conference Company eyes U.S. commercialization pending FDA clearance HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment. The findings, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society’s annual meeting in San Diego, validate HeartBeam’s compact, patient-friendly ECG technology. The study compared ECG intervals and amplitudes between HeartBeam’s synthesized output and simultaneously collected standard ECGs in 198 patients across…

Continue Reading

FridayJun 13, 2025 2:51 pm

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reported Q1 2025 Results, Advanced Toward Commercialization Following VALID-ECG Study Success

HeartBeam (NASDAQ: BEAT) reported financial results and operational highlights for the first quarter of 2025, marking significant progress toward commercialization of its 12-lead ECG synthesis software. The company successfully met clinical endpoints in its VALID-ECG pivotal study, demonstrating a 93.4% diagnostic agreement with standard ECGs, and engaged in productive discussions with the FDA on its 510(k) submission. During the quarter, HeartBeam entered a strategic collaboration with AccurKardia to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s compact, cable-free cardiac device. The partnership was expected to accelerate product development and improve access to rapid arrhythmia diagnosis. The company also expanded its intellectual…

Continue Reading

FridayJun 13, 2025 10:55 am

NetworkNewsBreaks – RedCloud Holdings plc (NASDAQ: RCT) to Participate in ROTH 15th Annual London Conference

RedCloud Holdings (NASDAQ: RCT) announced that CEO and Co-Founder Justin Floyd will attend the ROTH 15th Annual London Conference, taking place at the Four Seasons Hotel London at Park Lane. The event provides a platform for RedCloud to engage with investors and industry stakeholders in an international setting. To view the full press release, visit https://nnw.fm/b0bdT About RedCloud RedCloud has developed and operates the RedCloud trading platform (the “Platform”), that facilities trade of everyday consumer supplies of fast-moving consumer goods (“FMCG”) products across business supply chains. RedCloud believes its Platform solves a decades old problem of how to unlock and…

Continue Reading

ThursdayJun 12, 2025 10:35 am

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights Growth and SEPA Funding Ahead of BIO 2025 CEO Participation

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that CEO Amir Reichman will participate in the BIO International Convention 2025, taking place June 16–19 in Boston. The company will present recent strategic, operational, and financial milestones, including its rapid CDMO business growth and progress on its nanobody pipeline. Scinai recently secured $1.38 million in funding via its Standby Equity Purchase Agreement with Yorkville Advisors, boosting capital without warrants or additional dilution. The company reaffirmed 2025 CDMO revenue guidance of $2 million and targets breakeven in 2026. To view the full press release, visit https://nnw.fm/0j1hv About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company…

Continue Reading

ThursdayJun 12, 2025 10:24 am

NetworkNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Files Updated Resource Estimate for Condor Gold Project in Ecuador 

Silvercorp Metals (TSX: SVM) (NYSE American: SVM)  has filed an updated mineral resource estimate for its Condor gold project in Ecuador. The filing follows its May 12, 2025, announcement and includes the "Independent Technical Report for the Condor Project, Ecuador," prepared by SRK Consulting (Canada) Inc., with an effective date of Feb. 28, 2025. To view the full press release, visit https://nnw.fm/rZxrw About Silvercorp Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and growth potential. The Company's strategy is to create shareholder value by 1) focusing on generating free cash…

Continue Reading

ThursdayJun 12, 2025 9:10 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics to Present at H.C. Wainwright Neuro Perspectives Conference

NRx Pharmaceuticals (NASDAQ: NRXP) and its wholly owned subsidiary HOPE Therapeutics, Inc. announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, set for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx and Co-CEO of HOPE, will deliver a corporate presentation highlighting recent developments, available on demand to registered attendees starting at 7 a.m. ET on June 16. The company will also conduct one-on-one investor meetings during the event. To view the full press release, visit https://nnw.fm/xvy5t About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA…

Continue Reading

ThursdayJun 12, 2025 9:00 am

NetworkNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Launches Exploration at Storm Copper Project in Nunavut

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF) announced the start of exploration activities at its Storm Copper Project on Somerset Island, Nunavut. Operated by American West Metals under a 20/80 joint venture, with Aston Bay retaining a free carried interest until a mining decision follows a bankable feasibility study, the program will include reverse circulation and diamond drilling targeting both resource expansion and deeper discoveries. A MobileMT geophysical survey is also being deployed, expected to identify new drill targets this season. A Preliminary Economic Analysis for the near-surface mineralization is underway, with additional drill plans progressing for the company’s Epworth copper…

Continue Reading

WednesdayJun 11, 2025 3:16 pm

NetworkNewsBreaks – Alphabet Inc. (NASDAQ: GOOGL) (NASDAQ: GOOG) Trades Below S&P 500 Amid “Value Trap” Debate 

Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) is currently valued at ~19× forward earnings—below the S&P 500 average of 22.5×—making it the cheapest of the “Magnificent Seven” and sparking discussion about whether its low price represents value or a potential trap. While its search dominance is under siege from AI challengers like ChatGPT and regulatory pressure could force asset divestitures, Alphabet also boasts strong assets—YouTube, Google Cloud, and Waymo—plus a $70 billion share buyback plan and reliable dividend yield that suggest hidden upside. As of 5:00 p.m. ET on June 11, 2025, Alphabet stock (NASDAQ: GOOG) is trading at $179.13, down $0.88 (―0.49%), with intraday…

Continue Reading

WednesdayJun 11, 2025 3:00 pm

NetworkNewsBreaks – Meta Platforms Inc. (NASDAQ: META) Expands ‘Below Expectations’ Ratings in Midyear Reviews

Meta Platforms (NASDAQ: META) is reportedly preparing to invest approximately $14.8 billion for a 49% stake in Scale AI, a leading provider of data-labeling services critical to AI model training. As part of the deal, Scale AI’s CEO, Alexandr Wang, will join Meta to spearhead a new “superintelligence” lab alongside a 50person research team personally led by Mark Zuckerberg. The move comes in the wake of underperforming Llama 4 and delays to the “Behemoth” flagship AI model, making this Meta’s boldest strategic pivot in AI to date. On the regulatory front, U.S. antitrust authorities—particularly the FTC and DOJ—are scrutinizing even minority investments under…

Continue Reading